PROK News & Events

ProKidney (PROK) announced the appointment of Kenneth Locke as chief technical officer. Locke joins ProKidney from Carisma Therapeutics (CARM), where he oversaw CMC, Quality and Regulatory functions and led technical strategy for first-in-human CAR Myeloid programs.

Reports Q1 revenue $226,000, consensus $100,250."As we progress through 2026, we continue to build on the momentum established last year through positive Phase 2 REGEN-007 results, alignment with the FDA on the accelerated approval pathway, and meaningful progress on Phase 3 PROACT 1 study enrollment," said Bruce Culleton, M.D., CEO of ProKidney. "We expect to complete enrollment in PROACT 1 this year, positioning us to deliver pivotal eGFR slope topline results in the second quarter of 2027. Our mission remains highly focused on advancing a potential new treatment option for patients with advanced CKD and diabetes at high risk of kidney failure, an area of significant unmet medical need."

The company said, "Cash, cash equivalents and marketable securities as of March 31, 2026, totaled $224.9 million, compared to $270.0 million as of December 31, 2025. We expect that our existing cash, cash equivalents and marketable securities held at March 31, 2026, will enable us to fund our operating expenses and capital expenditure requirements into mid-2027."

ProKidney (PROK) announced the appointment of Greg Madison as chief commercial officer. In this role, Madison will drive ProKidney's commercial strategy as the company advances towards the potential commercialization of rilparencel. Most recently, he served as CEO of Shield Therapeutics (SHIEF).